Brown W A
Brown University School of Medicine, Providence, Rhode Island.
Neuropsychopharmacology. 1994 Jul;10(4):265-9; discussion 271-88. doi: 10.1038/npp.1994.53.
The placebo response rate in depression consistently falls between 30 and 40%. Among more severely depressed patients antidepressants offer a clear advantage over placebo; among less severely depressed patients and those with a relatively short episode duration the placebo response rate is close to 50% and often indistinguishable from the response rate to antidepressants. In the treatment of depression none of the psychotherapies have consistently been shown to offer an advantage over pill placebo. This is not entirely surprising given the fact that the common, and arguably the therapeutic, features of the psychotherapies (expectation of improvement, support, mobilization of hope) are provided with pill placebo treatment. The placebo response in depression has been viewed as a nuisance rather than as a therapeutic and research opportunity. I propose that the initial treatment for selected depressed patients should be four to six weeks of placebo. Patients so treated should be informed that the placebo pill contains no drug but that this treatment can be helpful.
抑郁症的安慰剂反应率一直介于30%至40%之间。在病情较重的抑郁症患者中,抗抑郁药比安慰剂具有明显优势;在病情较轻以及发作持续时间相对较短的患者中,安慰剂反应率接近50%,且常常与抗抑郁药的反应率难以区分。在抑郁症治疗中,没有任何一种心理疗法始终被证明比服用安慰剂更具优势。鉴于心理疗法常见且可被视为具有治疗作用的特征(对改善的期望、支持、唤起希望)在服用安慰剂治疗中也能实现,这并不完全令人惊讶。抑郁症中的安慰剂反应一直被视为一种麻烦,而非一个治疗和研究机会。我提议,对于部分选定的抑郁症患者,初始治疗应为服用四周至六周的安慰剂。应告知接受这种治疗的患者,安慰剂片中不含药物,但这种治疗可能会有帮助。